UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/588,310	08/03/2006	Kyoko Miura	016912-0217	6869
22428 FOLEY AND I	7590 01/10/2008 ARDNER I I P		EXAMINER	
SUITE 500			LAMM, MARINA	
3000 K STREE WASHINGTO			ART UNIT PAPER NUMBER	
Wildimidio	N, DC 20007		1617	
•			[DELIVERY MODE
			MAIL DATE	DELIVERY MODE
•		•	01/10/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

•		Application No.	Applicant(s)
Office Action Summary		10/588,310	MIURA ET AL.
		Examiner	Art Unit
		Marina Lamm	1617
Period fo	The MAILING DATE of this communication app	ears on the cover sheet with the c	orrespondence address
A SH WHIC - Exter after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DANS IN THE MAIL	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).
Status			
2a)	Responsive to communication(s) filed on This action is FINAL . 2b) This Since this application is in condition for allowar closed in accordance with the practice under <i>E</i>	_ action is non-final. nce except for formal matters, pro	
Dispositi	on of Claims	•	•
5)☐ 6)⊠ 7)☐ 8)☐ Applicati 9)☐ 10)☐	Claim(s) 1-4 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed. Claim(s) 1-4 is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction and/or on Papers The specification is objected to by the Examiner The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the or Replacement drawing sheet(s) including the correction of the oath or declaration is objected to by the Examiner The oath or declaration is objected to by the Examiner Contents of the oath or declaration is objected to by the Examiner Contents of the oath or declaration is objected to by the Examiner Contents of the oath or declaration is objected to by the Examiner Contents of the oath or declaration is objected to by the Examiner Contents of the oath or declaration is objected to by the Examiner Contents of the oath or declaration is objected to by the Examiner Contents of the oath or declaration is objected to by the Examiner Contents of the oath or declaration is objected to by the Examiner Contents of the oath or declaration is objected to by the Examiner Contents of the oath or declaration is objected to by the Examiner Contents of the oath or declaration is objected to by the Examiner Contents of the oath or declaration is objected to by the Examiner Contents of the oath or declaration is objected to by the Examiner Contents of the oath or declaration is objected to by the Examiner Contents of the oath or declaration is objected to by the Examiner Contents of the oath or declaration is objected to by the Examiner Contents of the oath or declaration is objected to by the Examiner Contents of the oath or declaration is objected to be objected	election requirement. r. epted or b) objected to by the Edrawing(s) be held in abeyance. See on is required if the drawing(s) is objected to by the drawing(s) is o	37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).
	ınder 35 U.S.C. § 119		
12)⊠ / a)[Acknowledgment is made of a claim for foreign All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priori application from the International Bureau see the attached detailed Office action for a list of	have been received. have been received in Application ity documents have been received (PCT Rule 17.2(a)).	on No d in this National Stage
2) Notice 3) Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO/SB/08) ' No(s)/Mail Date 8/3/06.	4) Interview Summary (Paper No(s)/Mail Dat 5) Notice of Informal Pa 6) Other:	e

Art Unit: 1617

DETAILED ACTION

Claims 1-4 are pending in this application filed 8/3/06, which is a 371 of PCT/JP05/01572, filed 2/3/05, which claims priority to Japanese applications 2004-027613 and 2004-197414, filed 2/4/04 and 6/7/04, respectively. Acknowledgment is made of the preliminary amendment filed 8/3/06.

Double Patenting

1. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

2. Claims 1-4 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 23, 24, 26, 31 and 39 of copending Application No. 10/531,176. An obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but an examined

Art Unit: 1617

application claim is not patentably distinct from the reference claim(s) because the examined claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985). Although the conflicting claims are not identical, they are not patentably distinct from each other because Claims 1-4 are anticipated by Claims 23, 24, 26, 31 and 39 of copending Application No. 10/531,176. Specifically, the N-acetylglucosamine esters of the instant claims are the same as compounds as those claimed in the claims of copending Application No. 10/531,176.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claim Rejections - 35 USC § 102

3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States
- 4. Claims 1-4 are rejected under 35 U.S.C. 102(b) as being anticipated by Shimizu (JP 02243611, translation), cited by the Applicant.

Shimizu teaches cosmetic compositions containing 5-50% of N-acetylglucosamine esters with fatty acids preferably having 8-22 carbon atoms such as palmitic acid, stearic acid, oleic acid, isopalmitic acid and isostearic acid. See translation

Art Unit: 1617

@ p. 5, Examples. The recitation of intended use in the instant claims, i.e. "antiwrinkle agent", is not given any patentable weight. The courts have held that in composition claims "intended use must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim." See *In re Casey*, 152 USPQ 235 (CCPA 1967); *In re Otto*, 136 USPQ 458, 459 (CCPA 1963)

Thus, Shimizu teaches each and every limitation of Claims 1-4.

Conclusion

5. No claim is allowed at this time.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Marina Lamm whose telephone number is (571) 272-0618. The examiner can normally be reached on Mon-Fri from 11am to 7pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan, can be reached at (571) 272-0629.

The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private

Page 5

PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Marina Lamm, M.S.

Patent Examine

1/5/08

SHEENI PADMANABRAN SUPERVISORY PATENT EXAMENER